Nieves Martinez Lago Shared a Study on Mifamurtide in localized Osteosarcoma
Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X about a paper by Emanuela Palmerini et al. published in the Journal of Clinical Oncology:
“Mifamurtide in localized osteosarcoma (ISG/OS-2 & GEIS-33)
- 398 pts, median age 14y
- 53% Pgp+, 51% received mifamurtide
- 5y EFS 65.2%, OS 74.8%
- Better EFS with mifamurtide + chemo vs CT alone (71.4% vs 58.3%), not confirmed in multivariable.”
Title: Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
Authors: Emanuela Palmerini, Cristina Meazza, Angela Tamburini, Catalina Márquez-Vega, Gianni Bisogno, Franca Fagioli, Virginia Ferraresi, Giuseppe Maria Milano, Luca Coccoli, Alba Rubio-San-Simón, Oscar Gallego, María Esther Llinares Riestra, Carla Manzitti, Jaume Mora, Mᵃ Ángeles Vaz-Salgado, Roberto Luksch, Cristina Mata, Michela Pierini, Elisa Carretta, Marilena Cesari, Anna Paioli, Andrea Marrari, Katia Scotlandi, Massimo Serra, Sebastian Dorin Asaftei, Marco Gambarotti, Piero Picci, Stefano Ferrari, Claudia Valverde, Toni Ibrahim, Javier Martín Broto
Read the Full Article on the Journal of Clinical Oncology.
More posts featuring Nieves Martinez Lago.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023